Tristão-Pereira C, Fuster V, Lopez-Jimenez A, Fernández-Pena A, Semerano A, Fernandez-Nueda I, Garcia-Lunar I, Ayuso C, Sanchez-Gonzalez J, Ibanez B, Gispert JD, Cortes-Canteli M.
Rationale: Cognitive decline and dementia have been reportedly linked to atherosclerosis, the main cause of cardiovascular disease. Cohort studies identifying early brain alterations associated with subclinical atherosclerosis are warranted to understand the potential of prevention strategies before cerebral damage becomes symptomatic and irreversible.
Methods & design: The Progression of Early Subclinical Atherosclerosis (PESA) study is a longitudinal observational cohort study that recruited 4184 asymptomatic middle-aged individuals (40-54 years) in 2010 in Madrid (Spain) to thoroughly characterize subclinical atherosclerosis development over time. In this framework, the PESA-Brain study has been designed to identify early structural, functional and vascular brain changes associated with midlife atherosclerosis and cardiovascular risk factors. The PESA-Brain study targets 1000 participants at the 10-year follow-up PESA visit and consists of thorough neuropsychological testing, advanced multi-modal neuroimaging, and quantification of blood-based neuropathological biomarkers.
Primary hypothesis: We hypothesized that, in middle-age, the presence of cardiovascular risk factors and a high burden of subclinical atherosclerosis will be associated with structural, functional and vascular brain alterations, greater amyloid burden and subtle cognitive impairment. We further hypothesize that the link between subclinical atherosclerosis and poor brain health in midlife will be mediated by cerebrovascular pathology and intracranial atherosclerosis.
Enrollment dates: The PESA-Brain study started in October 2020 and is estimated to be completed by December 2024.
Conclusion: This study is in a unique position to unveil novel relationships between cardiovascular and brain alterations in the health-to-disease transition, which may have important implications for interventional and therapeutic approaches. TRIAL REGISTRATION - REGISTRY: clinicaltrials.gov; Registration Number: NCT01410318; url: https://clinicaltrials.gov/study/NCT01410318.
Tristão-Pereira C, Fuster V, Lopez-Jimenez A, Fernández-Pena A, Semerano A, Fernandez-Nueda I, Garcia-Lunar I, Ayuso C, Sanchez-Gonzalez J, Ibanez B, Gispert JD, Cortes-Canteli M. Subclinical atherosclerosis and brain health in midlife: Rationale and design of the PESA-Brain study. Am Heart J. 2024 Sep 23:S0002-8703(24)00261-8. doi: 10.1016/j.ahj.2024.09.028. Epub ahead of print. PMID: 39322173.